Table 4. Reactions and Health Impacts Reported in v-safe Respondents.

Reaction	Simultaneous influenza and COVID-19 mRNA booster vaccine received, aOR (95% CI)a,b (N = 92 023)
	Pfizer-BioNTech (n = 61 390)	Moderna (n = 30 633)
Any injection site reaction	1.10 (1.08-1.12)	1.05 (1.02-1.08)
Any systemic reaction	1.08 (1.06-1.10)	1.11 (1.08-1.14)
Any health impactc	0.99 (0.97-1.02)	1.05 (1.02-1.08)
Unable to perform normal daily activities	0.99 (0.97-1.01)	1.04 (1.01-1.07)
Unable to work or attend school	1.04 (1.01– 1.07)	1.08 (1.04-1.12)
Needed medical care	0.92 (0.84-1.01)	0.94 (0.83-1.07)

^a Includes persons who completed at least one v-safe health check-in survey on days 0 to 7 after vaccination. Odds ratios were adjusted for age at vaccination, sex, and week of vaccination.

^b Simultaneous vaccination was defined as persons who received a COVID-19 mRNA booster vaccine and seasonal influenza vaccine during the same visit. A booster dose was defined as dose 3 of a COVID-19 mRNA vaccine administered ≥5 months after dose 2, on or after booster doses were authorized for each manufacturer and age group.

^c Any health impact was defined as persons who reported they were unable to perform normal daily activities, missed work or school, or received care from a medical professional because of new symptoms or conditions.